Kawasaki disease and cardiac involvement: an update on the state of the art.
J Biol Regul Homeost Agents
; 34(4 Suppl. 2): 47-53. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY, 2020.
Article
en En
| MEDLINE
| ID: mdl-33000600
ABSTRACT
Kawasaki disease (KD) is an acute systemic vasculitis of unknown etiology. It has a self-limiting course and so far, represents the most common cause of coronary heart disease acquired in children aged between 6 months and 5 years. The inflammatory process can involve the coronary arteries with the formation of aneurysms and thrombotic occlusions with the risk of sudden death, especially in infants. Myocardial inflammation and abnormalities of cardiac contractility can occur acutely or many years after the disease onset. Therapy must be started within 10 days after the onset of symptoms to reduce the risk of heart complications. Immunoglobulin and aspirin treatment are effective in reducing heart complications. Recent studies have shown new therapeutic strategies (corticosteroids, immunosuppressive and biological drugs) in case of ineffectiveness of treatment with immunoglobulins.
Palabras clave
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Cardiopatías
/
Síndrome Mucocutáneo Linfonodular
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
Límite:
Child, preschool
/
Humans
/
Infant
Idioma:
En
Revista:
J Biol Regul Homeost Agents
Asunto de la revista:
BIOLOGIA
/
BIOQUIMICA
Año:
2020
Tipo del documento:
Article
País de afiliación:
Italia